Table 2 Histologic features of the NAFLD patients.

From: Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease

Factor

Total (N = 114)

No fibrosis (F0) (N = 63)

Fibrosis (F1–3) (N = 51)

p-value

Steatosis

0.000†

 < 5%

57 (50.0)

45 (71.4)

12 (23.5)

 

5–33%

42 (36.8)

18 (28.6)

24 (47.1)

 

34–65%

12 (10.5)

0 (0.0)

12 (23.5)

 

 ≥ 66%

3 (2.6)

0 (0.0)

3 (5.9)

 

Portal inflammation (under 20 ×)

0.000†

None

51 (44.7)

45 (71.4)

6 (11.8)

 

 < 2

45 (39.5)

18 (28.6)

27 (52.9)

 

2–4

9 (7.9)

0 (0.0)

9 (17.6)

 

 > 4

9 (7.9)

0 (0.0)

9 (17.6)

 

Ballooning

0.000†

None

27 (23.7)

18 (28.6)

9 (17.6)

 

Few

75 (65.8)

45 (71.4)

30 (58.8)

 

Many

12 (10.5)

0 (0.0)

12 (23.5)

 

NAS§

3.29 ± 2.03

2.29 ± 1.17

4.53 ± 2.19

0.000‡

  1. Values presented as mean ± standard deviation or N (column %).
  2. NAFLD non-alcoholic fatty liver disease, NAS§ NAFLD activity score.
  3. Fibrosis was scored as F0, no fibrosis; F1, portal fibrosis without septae; F2, portal fibrosis with septae; F3, numerous septae without cirrhosis; and F4, cirrhosis.
  4. NAFLD patients and non-NAFLD patients.
  5. p-values: †Pearson’s chi-squared test, ‡Student's t‐test.
Back to article page